Phase 3 Readout
COSM: Phase 3 Topline: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patient
September 30, 2027 · blinatumomab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 30, 2027
- Company
- Cosmos Health Inc. (COSM)
- Drug
- blinatumomab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patient
- Company
- Cosmos Health Inc. (COSM)
- Drug
- blinatumomab
- Indication
- Down Syndrome; B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma